Glide Technologies is a clinical stage development company focused on solid dose formulations of therapeutics and vaccines. Glide has a growing pipeline of products based on its proprietary solid dose injector, the Glide SDI® , which offers the potential of improved compliance in long term therapy and enhanced immune responses to vaccines. Glide’s pipeline of solid dose formulations includes octreotide, teriparatide (PTH 1-34), exenatide and anthrax and influenza vaccines.
A first clinical study with octreotide SDI® was completed successfully in the first half of 2016 and a second clinical study, with teriparatide SDI®, is planned for 2017. The Glide solid dose injector (‘SDI®’) has undergone successful human factor and surrogate skin injection studies.
The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. Glide Technologies is supported by institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.